<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514449</url>
  </required_header>
  <id_info>
    <org_study_id>0602032</org_study_id>
    <nct_id>NCT00514449</nct_id>
  </id_info>
  <brief_title>Systematic Evaluation of Antiviral Medication in Schizophrenia</brief_title>
  <acronym>SEAMS</acronym>
  <official_title>A Randomized Double-blind Controlled Trial of Valacyclovir Add-on Treatment of HSV Positive Early Course Schizophrenia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konasale Prasad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether antiviral medication will help improve
      psychotic symptoms and cognition in individuals early in the course of schizophrenia or
      schizoaffective disorder who are exposed to herpes simplex virus, type 1 (HSV 1), a virus
      that causes commonly occurring and recurrent cold sores.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the study is to evaluate the efficacy of add-on treatment of
      Valacyclovir (VAV), an antiviral medication, in the treatment of early course
      schizophrenia/schizoaffective disorder patients. Our main hypothesis is that the VAV add-on
      treatment will improve positive, negative and cognitive symptoms in herpes simplex virus
      (HSV) positive schizophrenia or schizoaffective disorder patients. We hypothesize that the
      grey matter reductions in specific brain regions (such as prefrontal regions) will improve in
      patients on VAV + antipsychotic compared to those on placebo + antipsychotic and the
      improvements in positive, negative and cognitive symptoms will be correlated with the grey
      matter changes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS Positive and Negative Syndrome Scale for Schizophrenia</measure>
    <time_frame>Baseline, Weeks 2, 4, 6, 10, 14, 18</time_frame>
    <description>This is a structured measure of severity of psychopathology that includes both positive and negative symptoms. The range is a minimum score of 30 and the maximum is 210. The lower scores suggest milder severity of illness domains.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive Function Neuropsychological Battery (Gur Battery)</measure>
    <time_frame>Baseline, Week 18</time_frame>
    <description>All results are given as the mean difference between an 18 week follow-up and the baseline battery administrations.This is a computerized test that measures both accuracy and response times. A range for response times is not available because of individual variabilities. Accuracy scores can vary for each test: Working memory accuracy range was 0-16. Verbal memory accuracy range was 0-20. For both, the higher the score the better. No cut offs are available</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Grey Matter Deficit</measure>
    <time_frame>Baseline, Week 18</time_frame>
    <description>Gray matter volume changes (in cc) were measured using structural MRI. Changes were reported as gray matter volume in cc. Note: Assessment of blood oxygenation level dependent (BOLD) changes using fMRI were erroneously included in the original study record.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Valacyclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <description>1 g PO BID x 2 weeks after 2 weeks it goes up to 1.5 g PO BID x 16 weeks along with antipsychotic</description>
    <arm_group_label>Valacyclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both genders between the ages of 18-50 years

          -  Schizophrenia or schizoaffective disorder as defined in DSM-IV

          -  Duration of illness 10 years or less

          -  On a stable dose of an antipsychotic medication for at least a month

          -  Should score 4 or more on at least one of the subscales of PANSS

          -  Positive for HSV1

          -  Written informed consent

        Exclusion Criteria:

          -  Substance abuse in the last month/dependence 6 months prior to the study

          -  History of, or current medical/neurological illnesses which affects CNS function e.g.,
             epilepsy, head injury with prolonged loss of consciousness

          -  Pregnancy

          -  History of immune disorders, HIV infection or currently receiving immunosuppressants

          -  Subjects on regular antiviral therapy

          -  History of hypersensitivity to Valacyclovir

          -  Mental retardation as defined in DSM-IV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konasale Prasad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Psychiatric Institute and Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vishwajit Nimgaonkar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Psychiatric Institute and Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matcheri Keshavan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajaprabhakaran Rajarethinam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Psychiatric Institute and Clinic</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Prasad KM, Shirts BH, Yolken RH, Keshavan MS, Nimgaonkar VL. Brain morphological changes associated with exposure to HSV1 in first-episode schizophrenia. Mol Psychiatry. 2007 Jan;12(1):105-13, 1. Epub 2006 Oct 10.</citation>
    <PMID>17033628</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2007</study_first_posted>
  <results_first_submitted>December 2, 2011</results_first_submitted>
  <results_first_submitted_qc>May 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2018</results_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Konasale Prasad</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited between 7/2007 and 8/2009 at two separate sites, Pittsburgh and Detroit. Recruitment took place through the local hospital and community mental health and school counseling centers, as well as other research studies and area mental health conferences.</recruitment_details>
      <pre_assignment_details>Patients first had a placebo run-in for two weeks along with the psychiatric medications they were on and then randomized at Week 2 to either VAV or placebo group. Enrolled subjects were excluded due to cannabis abuse, claustrophobia, and a duration of illness that was too long.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Valacyclovir</title>
          <description>1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Valacyclovir</title>
          <description>1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.6" spread="9.4"/>
                    <measurement group_id="B2" value="28.7" spread="8.5"/>
                    <measurement group_id="B3" value="29.2" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PANSS Positive and Negative Syndrome Scale for Schizophrenia</title>
        <description>This is a structured measure of severity of psychopathology that includes both positive and negative symptoms. The range is a minimum score of 30 and the maximum is 210. The lower scores suggest milder severity of illness domains.</description>
        <time_frame>Baseline, Weeks 2, 4, 6, 10, 14, 18</time_frame>
        <population>Comparative analysis of active drug versus placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Valacyclovir</title>
            <description>1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PANSS Positive and Negative Syndrome Scale for Schizophrenia</title>
          <description>This is a structured measure of severity of psychopathology that includes both positive and negative symptoms. The range is a minimum score of 30 and the maximum is 210. The lower scores suggest milder severity of illness domains.</description>
          <population>Comparative analysis of active drug versus placebo</population>
          <units>Scores on the scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scores at Baseline of the trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.08" spread="12.616"/>
                    <measurement group_id="O2" value="83.92" spread="13.895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scores at week 2 of the trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.25" spread="11.450"/>
                    <measurement group_id="O2" value="77" spread="14.917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scores at week 4 of the trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.36" spread="12.314"/>
                    <measurement group_id="O2" value="75.2" spread="13.998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scores at week 6 of the trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.583" spread="9.228"/>
                    <measurement group_id="O2" value="74.3" spread="16.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scores at week 10 of the trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2" spread="10.737"/>
                    <measurement group_id="O2" value="73.2" spread="12.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scores at week 14 of the trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1" spread="12.511"/>
                    <measurement group_id="O2" value="69.6" spread="14.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scores at the end of the trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5" spread="9.289"/>
                    <measurement group_id="O2" value="67.125" spread="13.726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cognitive Function Neuropsychological Battery (Gur Battery)</title>
        <description>All results are given as the mean difference between an 18 week follow-up and the baseline battery administrations.This is a computerized test that measures both accuracy and response times. A range for response times is not available because of individual variabilities. Accuracy scores can vary for each test: Working memory accuracy range was 0-16. Verbal memory accuracy range was 0-20. For both, the higher the score the better. No cut offs are available</description>
        <time_frame>Baseline, Week 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valacyclovir</title>
            <description>1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Function Neuropsychological Battery (Gur Battery)</title>
          <description>All results are given as the mean difference between an 18 week follow-up and the baseline battery administrations.This is a computerized test that measures both accuracy and response times. A range for response times is not available because of individual variabilities. Accuracy scores can vary for each test: Working memory accuracy range was 0-16. Verbal memory accuracy range was 0-20. For both, the higher the score the better. No cut offs are available</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Working Memory: 2-Back Test Accuracy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" spread="2.68"/>
                    <measurement group_id="O2" value="0.13" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediate Verbal Memory Reaction Accuracy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="2.62"/>
                    <measurement group_id="O2" value="-0.49" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Grey Matter Deficit</title>
        <description>Gray matter volume changes (in cc) were measured using structural MRI. Changes were reported as gray matter volume in cc. Note: Assessment of blood oxygenation level dependent (BOLD) changes using fMRI were erroneously included in the original study record.</description>
        <time_frame>Baseline, Week 18</time_frame>
        <population>Analysis included on all participants on whom baseline and week 18 data were collected. Valacyclovir and placebo groups</population>
        <group_list>
          <group group_id="O1">
            <title>Valacyclovir</title>
            <description>A time by treatment group interaction showed increased gray matter volume estimated as number of voxels in a cluster with Valaclcovir compared to placebo</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>A time by treatment group interaction showed decreased or no significant change in the gray matter volume estimated as number of voxels in a cluster with Valaclcovir compared to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Grey Matter Deficit</title>
          <description>Gray matter volume changes (in cc) were measured using structural MRI. Changes were reported as gray matter volume in cc. Note: Assessment of blood oxygenation level dependent (BOLD) changes using fMRI were erroneously included in the original study record.</description>
          <population>Analysis included on all participants on whom baseline and week 18 data were collected. Valacyclovir and placebo groups</population>
          <units>cc</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.83" spread="5.04"/>
                    <measurement group_id="O2" value="24.22" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>p value is adjusted for multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <param_type>number of voxels in a cluster</param_type>
            <param_value>2037</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Time by treatment group interaction term</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2, 4, 6, 10, 14, and 18 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Valacyclovir</title>
          <description>1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach Bloating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Stomach Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in Elbow when Extended</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Leg Cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Motion Sickness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tongue Twitch</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Slight Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mild Extrapyramidal Symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Increased Sexual Drive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a small sample study designed as a proof of concept. A larger study will follow.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Konasale Prasad</name_or_title>
      <organization>Western Psychiatric Institute and Clinic</organization>
      <phone>412-586-9014</phone>
      <email>prasadkm@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

